Shanghai Seizes Cell Samples As China Tightens Biosecurity Enforcement
First Action Since 15 April Law Enactment
Executive Summary
Authorities in China appear to be taking a tough early stance in the enforcement of a new national Biosecurity Law that took effect in mid-April, with an imported human cell shipment in Shanghai being seized.
You may also be interested in...
A Dark Horse Five Years In The Making: Legend Gains First Global Approval
Nanjing Legend gains FDA approval for its BCMA cell therapy, the second to go to market in the US marks a win for true innovators from China, not cheaper but similar products, some say.
China Cancer Drug Off-Label Use: A Crossed Line?
Off-label use of cancer drugs in China is legal and even common in certain cases. But a line has been crossed in cases of active promotion and even conflicts of interest for some high-priced products and unproven cell therapies, unveiled by a Chinese physician whistleblower, regulatory observers say.
China Detains Legend Biotech CEO, Exposes Genetic Material Minefield
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.